BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
asciminib Sensitive: B - Late Trials
Novartis Press Release - 1 week (New B)
|
asciminib Sensitive: B - Late Trials
Novartis Press Release - 1 week - (New B)
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
dasatinib Sensitive: A1 - Approval
|
dasatinib Sensitive: A1 - Approval
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
asciminib Sensitive: A1 - Approval
|
asciminib Sensitive: A1 - Approval
|
No biomarker
|
CML
|
No biomarker
|
CML
|
omacetaxine mepesuccinate Sensitive: A1 - Approval
|
omacetaxine mepesuccinate Sensitive: A1 - Approval
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
CML
|
No biomarker
|
CML
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
ABL1 T315I
|
CML
|
ABL1 T315I
|
CML
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
Chr t(1;16)(q12;q11.2)
|
CML
|
Chr t(1;16)(q12;q11.2)
|
CML
|
ponatinib Sensitive: A1 - Approval
|
ponatinib Sensitive: A1 - Approval
|
No biomarker
|
CML
|
No biomarker
|
CML
|
busulfan Sensitive: A1 - Approval
|
busulfan Sensitive: A1 - Approval
|
No biomarker
|
CMML
|
No biomarker
|
CMML
|
azacitidine Sensitive: A1 - Approval
|
azacitidine Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
nilotinib Sensitive: A1 - Approval
|
nilotinib Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
bosutinib Sensitive: A1 - Approval
|
bosutinib Sensitive: A1 - Approval
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
No biomarker
|
CMML
|
No biomarker
|
CMML
|
decitabine/cedazuridine Sensitive: A1 - Approval
|
decitabine / cedazuridine Sensitive: A1 - Approval
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
asciminib Sensitive: A1 - Approval
|
asciminib Sensitive: A1 - Approval
|
BCR-ABL1 V299L
|
CML
|
BCR-ABL1 V299L
|
CML
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
No biomarker
|
CML
|
No biomarker
|
CML
|
bosutinib Sensitive: A2 - Guideline
|
bosutinib Sensitive: A2 - Guideline
|
No biomarker
|
CML
|
No biomarker
|
CML
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
No biomarker
|
CML
|
No biomarker
|
CML
|
dasatinib Sensitive: A2 - Guideline
|
dasatinib Sensitive: A2 - Guideline
|
No biomarker
|
CML
|
No biomarker
|
CML
|
YD312 Sensitive: A2 - Guideline
|
YD312 Sensitive: A2 - Guideline
|
BCR-ABL1 F317L
|
CML
|
BCR-ABL1 F317L
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
Tyrosine kinase inhibitor Sensitive: A2 - Guideline
|
BCR-ABL1 V299L
|
CML
|
BCR-ABL1 V299L
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 T315A
|
CML
|
BCR-ABL1 T315A
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317I
|
CML
|
BCR-ABL1 F317I
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317V
|
CML
|
BCR-ABL1 F317V
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 F317C
|
CML
|
BCR-ABL1 F317C
|
CML
|
dasatinib Resistant: A2 - Guideline
|
dasatinib Resistant: A2 - Guideline
|
BCR-ABL1 Y253H
|
CML
|
BCR-ABL1 Y253H
|
CML
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 E255K
|
CML
|
BCR-ABL1 E255K
|
CML
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 E255V
|
CML
|
BCR-ABL1 E255V
|
CML
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F359V
|
CML
|
BCR-ABL1 F359V
|
CML
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F359C
|
CML
|
BCR-ABL1 F359C
|
CML
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 F359I
|
CML
|
BCR-ABL1 F359I
|
CML
|
nilotinib Resistant: A2 - Guideline
|
nilotinib Resistant: A2 - Guideline
|
BCR-ABL1 G250E
|
CML
|
BCR-ABL1 G250E
|
CML
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
CML
|
BCR-ABL1 F317L
|
CML
|
bosutinib Resistant: A2 - Guideline
|
bosutinib Resistant: A2 - Guideline
|
BCR-ABL1 F317L
|
CML
|
BCR-ABL1 F317L
|
CML
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BCR-ABL1 L248V
|
CML
|
BCR-ABL1 L248V
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
olverembatinib Sensitive: B - Late Trials
|
olverembatinib Sensitive: B - Late Trials
|
BCR-ABL1 G250E
|
CML
|
BCR-ABL1 G250E
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 Q252H
|
CML
|
BCR-ABL1 Q252H
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 E255K
|
CML
|
BCR-ABL1 E255K
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 F359C
|
CML
|
BCR-ABL1 F359C
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 Y253H
|
CML
|
BCR-ABL1 Y253H
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 E355G
|
CML
|
BCR-ABL1 E355G
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 F359V
|
CML
|
BCR-ABL1 F359V
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 L387M
|
CML
|
BCR-ABL1 L387M
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 E459K
|
CML
|
BCR-ABL1 E459K
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 D276G
|
CML
|
BCR-ABL1 D276G
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 E279K
|
CML
|
BCR-ABL1 E279K
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 H396R
|
CML
|
BCR-ABL1 H396R
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 F486S
|
CML
|
BCR-ABL1 F486S
|
CML
|
dasatinib Sensitive: B - Late Trials
|
dasatinib Sensitive: B - Late Trials
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
ponatinib Sensitive: C1 - Off-label
|
ponatinib Sensitive: C1 - Off-label
|
TP53 mutation
|
CMML
|
TP53 mutation
|
CMML
|
venetoclax Sensitive: C1 - Off-label
|
venetoclax Sensitive: C1 - Off-label
|
RUNX1 mutation
|
CMML
|
RUNX1 mutation
|
CMML
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
CSF3R T618I
|
CML
|
CSF3R T618I
|
CML
|
ruxolitinib Sensitive: C3 – Early Trials
|
ruxolitinib Sensitive: C3 – Early Trials
|
ASXL1 mutation
|
CML
|
ASXL1 mutation
|
CML
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
IDH2 mutation
|
CMML
|
IDH2 mutation
|
CMML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
dasatinib + nilotinib Resistant: C3 – Early Trials
|
dasatinib + nilotinib Resistant: C3 – Early Trials
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
PF-114 Sensitive: C3 – Early Trials
|
PF-114 Sensitive: C3 – Early Trials
|
CIP2A-H
|
CML
|
CIP2A-H
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
miR-146a expression
|
CML
|
miR-146a expression
|
CML
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
IDH1 mutation
|
CMML
|
IDH1 mutation
|
CMML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
NPM1 mutation
|
CMML
|
NPM1 mutation
|
CMML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
venetoclax + nilotinib Sensitive: C3 – Early Trials
|
venetoclax + nilotinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
venetoclax + bosutinib Sensitive: C3 – Early Trials
|
venetoclax + bosutinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
venetoclax + ponatinib Sensitive: C3 – Early Trials
|
venetoclax + ponatinib Sensitive: C3 – Early Trials
|
BCR-ABL1 mutation
|
CML
|
BCR-ABL1 mutation
|
CML
|
venetoclax + dasatinib Sensitive: C3 – Early Trials
|
venetoclax + dasatinib Sensitive: C3 – Early Trials
|
BCR-ABL1 Q252H
|
CML
|
BCR-ABL1 Q252H
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
BCR-ABL1 M351T
|
CML
|
BCR-ABL1 M351T
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
BCR-ABL1 L248V
|
CML
|
BCR-ABL1 L248V
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
BCR-ABL1 F359V
|
CML
|
BCR-ABL1 F359V
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
KRAS G12A
|
CML
|
KRAS G12A
|
CML
|
GT19077 Sensitive: C3 – Early Trials
|
GT19077 Sensitive: C3 – Early Trials
|
G0S2 overexpression
|
CML
|
G0S2 overexpression
|
CML
|
YD312 Sensitive: C3 – Early Trials
|
YD312 Sensitive: C3 – Early Trials
|
DNMT3A deletion
|
CML
|
DNMT3A deletion
|
CML
|
EGFR inhibitor Resistant: C3 – Early Trials
|
EGFR inhibitor Resistant: C3 – Early Trials
|
ASXL1 deletion
|
CML
|
ASXL1 deletion
|
CML
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
KDM4D mutation
|
CML
|
KDM4D mutation
|
CML
|
imatinib Resistant: C3 – Early Trials
|
imatinib Resistant: C3 – Early Trials
|
DNMT3A mutation
|
CML
|
DNMT3A mutation
|
CML
|
YD312 Resistant: C3 – Early Trials
|
YD312 Resistant: C3 – Early Trials
|
ASXL1 mutation
|
CML
|
ASXL1 mutation
|
CML
|
YD312 Resistant: C3 – Early Trials
|
YD312 Resistant: C3 – Early Trials
|
ABL1 T315I
|
CML
|
ABL1 T315I
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 F317L
|
CML
|
ABL1 F317L
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 T315I + ABL1 M351T + ABL1 L387M
|
CML
|
ABL1 T315I + ABL1 M351T + ABL1 L387M
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 F359V
|
CML
|
ABL1 F359V
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 G250E
|
CML
|
ABL1 G250E
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 Y253H
|
CML
|
ABL1 Y253H
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 E255K
|
CML
|
ABL1 E255K
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 D276G
|
CML
|
ABL1 D276G
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 M351T
|
CML
|
ABL1 M351T
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
ABL1 L387M
|
CML
|
ABL1 L387M
|
CML
|
dasatinib Resistant: C3 – Early Trials
|
dasatinib Resistant: C3 – Early Trials
|
BCR-ABL1 A397P
|
CML
|
BCR-ABL1 A397P
|
CML
|
dasatinib Sensitive: C3 – Early Trials
|
dasatinib Sensitive: C3 – Early Trials
|